Advertisement
The investigational Tomophase OCT system is designed to enable theinterventional pulmonologist to clearly visualize sub-epithelial tissuestructures in the airway. The system, which is not FDA approved, utilizes anear-infrared emitting probe in a catheter which is integrated with aconventional video bronchoscope. The images captured by the research team atBeth Israel are from ex vivo human bronchial tissue. During the next severalmonths the Company plans to further this work in real-time in vivo clinicalstudies.
Advertisement
"Our goal at Tomophase is to use our proprietary optical technology tohelp clinicians image subsurface tissue at a level of resolution currentlyunavailable, while not exposing the patient to potentially harmful radiation,UV light or contrast agents," commented Dr. Peter Norris, CEO of Tomophase."We believe this research collaboration with Beth Israel Deaconess is animportant first step in the introduction of this breakthrough technology intoboth the research and clinical settings."
"The initial imaging results from the Tomophase OCT system appear to showremarkable clarity at greater tissue depths than other existing opticalimaging technologies," commented Dr. Ernst. "As such, it may ultimately proveuseful to clinicians in the enhanced evaluation of various pulmonary diseasestates. High-resolution OCT technology may also have the potential to providereal-time image evaluation of drug/tissue interactions. This ability mayprovide new insight regarding the treatment of pulmonary conditions such asasthma and COPD."
About Tomophase Corporation
Tomophase Corporation is a private company founded in 2003 based onproprietary technology innovations in the field of optical coherencetomography and its use to image tissue at high resolution. With Tomophase OCT,researchers and clinicians can observe tissue structure within 2-3 mm of thesurface without the use of radiation, UV light or image contrast agents.Tomophase is pursuing the first application of its technology in pulmonarymedicine for the visualization of airways. Future development areas includerespiratory therapy development, lung cancer management and surgical guidance.
More information on Tomophase Corporation can be found on the World WideWeb at http://www.tomophase.com.
This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.For further information: Dr. Peter Norris, CEO Tomophase Corporation P: (781) 229-5700 E: [email protected]
SOURCE Tomophase Corporation
